Allay Therapeutics raised $57.5M in Series D financing, co-led by Lightstone Ventures and ClavystBio, to support its Phase 2b trial for post-surgical pain management.

Jun 05, 2025•6 months ago

Amount Raised

$57.5 Million

Round Type

series d

San JoseBiotechnology

Investors

Hsbc Innovation BankingSg InnovateEdbiIpd CapitalBrandon CapitalVertex Ventures HealthcareVertex GrowthArboretum VenturesNeaClavyst BioLightstone Ventures

Description

Allay Therapeutics, a San Jose, CA-based biotech company, raised $57.5M in Series D financing. The company will use the funds to support its Phase 2b registration trial for ATX101 following TKA surgery. Lightstone Ventures and ClavystBio co-led the round, with participation from NEA and others. Additional venture debt financing was provided by IPD Capital and others.

Company Information

Company

Allay Therapeutics

Location

2720 ZANKER ROAD

San Jose, California, United States

About

Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. We believe an era of stalled innovation for pain management is over. From San Francisco to Singapore, our team has a passion for solving medical challenges that could benefit millions. We pursue our mission with the energy of a dynamic, global team of entrepreneurs, scientists, clinicians and innovators.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends